Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.1 SEK | -2.71% | -0.16% | +9.32% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.32% | 16Cr | - | ||
+5.66% | 11TCr | B+ | ||
+11.23% | 11TCr | B+ | ||
-0.38% | 2.19TCr | B | ||
-12.15% | 2.23TCr | B+ | ||
-7.66% | 1.86TCr | A- | ||
-36.52% | 1.81TCr | A- | ||
-10.09% | 1.7TCr | B | ||
+3.33% | 1.37TCr | C+ | ||
+36.58% | 1.24TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EGTX Stock
- Ratings Egetis Therapeutics AB